Found: 5
Select item for more details and to access through your institution.
IL-17E, a proinflammatory cytokine, has antitumor efficacy against several tumor types in vivo.
- Published in:
- Cancer Immunology, Immunotherapy, 2010, v. 59, n. 6, p. 805, doi. 10.1007/s00262-009-0802-8
- By:
- Publication type:
- Article
Virulizin<sup>®</sup> induces production of IL-17E to enhance antitumor activity by recruitment of eosinophils into tumors.
- Published in:
- Cancer Immunology, Immunotherapy, 2008, v. 57, n. 12, p. 1757, doi. 10.1007/s00262-008-0502-9
- By:
- Publication type:
- Article
Virulizin, a novel immunotherapy agent, activates NK cells through induction of IL-12 expression in macrophages.
- Published in:
- Cancer Immunology, Immunotherapy, 2005, v. 54, n. 11, p. 1115, doi. 10.1007/s00262-005-0698-x
- By:
- Publication type:
- Article
NK cell activation and tumor infiltration are involved in the antitumor mechanism of Virulizin.
- Published in:
- Cancer Immunology, Immunotherapy, 2005, v. 54, n. 3, p. 229, doi. 10.1007/s00262-004-0582-0
- By:
- Publication type:
- Article
Antitumor activity of Virulizin, a novel biological response modifier (BRM) in a panel of human pancreatic cancer and melanoma xenografts.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2003, v. 51, n. 3, p. 247, doi. 10.1007/s00280-002-0559-7
- By:
- Publication type:
- Article